These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 17628462)

  • 1. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medical outcomes and antimicrobial compliance according to the Chilean Society of Respiratory Diseases guidelines for hospitalized patients with community acquired pneumonia].
    Díaz A; Kuzmanic G; Platzer L; Sanfuentes F; Espinoza MA; Saldías F
    Rev Med Chil; 2003 Aug; 131(8):847-56. PubMed ID: 14558238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
    Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
    Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival.
    Bodí M; Rodríguez A; Solé-Violán J; Gilavert MC; Garnacho J; Blanquer J; Jimenez J; de la Torre MV; Sirvent JM; Almirall J; Doblas A; Badía JR; García F; Mendia A; Jordá R; Bobillo F; Vallés J; Broch MJ; Carrasco N; Herranz MA; Rello J;
    Clin Infect Dis; 2005 Dec; 41(12):1709-16. PubMed ID: 16288392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.
    Yoon YK; Kim EJ; Chun BC; Eom JS; Park DW; Sohn JW; Kim MJ
    Respirology; 2012 Jan; 17(1):172-9. PubMed ID: 21995414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
    Frei CR; Restrepo MI; Mortensen EM; Burgess DS
    Am J Med; 2006 Oct; 119(10):865-71. PubMed ID: 17000218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Respir Med; 2012 Mar; 106(3):451-8. PubMed ID: 22182341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
    Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
    Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
    Murcia JM; González-Comeche J; Marín A; Barberán J; Granizo JJ; Aguilar L; González-Moreno J; González-Pina B; López-Dupla M; Irurzun J;
    Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort.
    Wu JH; Howard DH; McGowan JE; Turpin RS; Henry Hu X
    Clin Ther; 2006 Sep; 28(9):1451-61. PubMed ID: 17062317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.